NCT00382668已完成不适用
Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects
Bristol-Myers Squibb4 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 4
研究概览
简要总结
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
A
干预措施: Dasatinib (Drug)
B
干预措施: Dasatinib (Drug)
C
干预措施: Dasatinib (Drug)
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic ImpairmentInsomniaNCT01257178Eli Lilly and Company
已完成
1 期
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver DysfunctionAttention Deficit Hyperactivity Disorder (ADHD)Binge-Eating Disorder DisorderNCT02795637Sumitomo Pharma America, Inc.44
已完成
1 期
Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionHealthyLiver DiseasesNCT02171832Boehringer Ingelheim32
已完成
1 期
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantNon-alcoholic Steatohepatitis (NASH)NCT05553470Corcept Therapeutics19
已完成
1 期
Evaluation Of Hepatic Impairment On AG-013736 PharmacokineticsHepatic InsufficiencyNCT00692341Pfizer24